Some clinical trials involving PD-L1 inhibitors showed a consistent correlation between the patient response rates and the PD-L1 expression level of the tumor (3), displaying that, for patients with high PD-L1 expression, utilization of immunotherapy such as pembrolizumab could significantly improve the clinical outcomes (4). Here, CD274 is linked to neoplasm.